Kewaunee Scienti Stock Price, News & Analysis

Kewaunee Scientific (NASDAQ: KEQU) reported strong Q1 FY2026 results with sales reaching $71.1 million, up 46.9% year-over-year. The company achieved net earnings of $3.1 million ($1.04 per diluted share), compared to $2.2 million ($0.74 per share) in the prior year.

The company's order backlog stood at $205.0 million as of July 31, 2025, up from $159.4 million year-over-year. Domestic segment sales increased 53.0% to $54.4 million, while International segment sales grew 30.2% to $16.8 million. The growth was partially driven by the incorporation of Nu Aire's results, following its acquisition in November 2024.

Despite anticipating uneven quarterly performance for the remainder of FY2026, management expects to deliver improved unadjusted EBITDA compared to FY2025, while continuing strategic investments in corporate infrastructure.

[ "Sales increased significantly by 46.9% to $71.1 million year-over-year", "Net earnings grew 41% to $3.1 million compared to prior year", "Strong order backlog of $205.0 million, up 28.6% from prior year", "Domestic segment sales surged 53.0% to $54.4 million", "International segment sales increased 30.2% to $16.8 million", "Debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1" ]

Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced its participation in the 2025 Arablab Live tradeshow in Dubai from September 23-25. The company will showcase its comprehensive portfolio, including products from its newly acquired subsidiary NuAire, and its healthcare brand EVERHUTCH.

Visitors can explore Kewaunee's booth at Hall 1, Stand F80 of the Dubai World Trade Centre, featuring demonstrations of new Revit design tools for laboratory planning. The presentation will highlight the company's integrated expertise in laboratory infrastructure, biosafety, healthcare environments, and data-informed lab design through its partnership with Koncepo.

Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced plans to release its first quarter fiscal year 2026 financial results on September 10, 2025 after market close. The company, founded in 1906, is a global leader in laboratory, healthcare, and technical furniture products manufacturing.

Kewaunee's portfolio includes steel and wood casework, fume hoods, modular systems, and biological safety cabinets. The company operates manufacturing facilities in Statesville, North Carolina and Bangalore, India, with sales offices across the US, India, Saudi Arabia, and Singapore. Through its recently acquired subsidiary Nu Aire, the company also manufactures laboratory products in Minnesota and maintains partnerships in the Netherlands and China.

Kewaunee Scientific Corporation (NASDAQ: KEQU) reported strong financial results for Q4 and fiscal year 2025. Q4 sales reached $77.1 million, up 36.1% year-over-year, with net earnings of $4.85 million and diluted EPS of $1.63. The company's order backlog stood at $214.6 million as of April 30, 2025.

The company completed the acquisition of Nu Aire, Inc. on November 1, 2024, strengthening its laboratory equipment portfolio. For the full fiscal year 2025, sales increased 18% to $240.5 million, with net earnings of $11.4 million. Adjusted for acquisition costs, fiscal year 2025 adjusted diluted EPS was $5.37, compared to $4.19 in the prior year.

The Domestic segment showed particularly strong performance with sales up 54.7% in Q4, while International segment sales increased by 3.9%. The company maintains a healthy financial position with $17.2 million in cash and a debt-to-equity ratio of 0.99-to-1.

Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced it will release its fourth quarter and fiscal year 2025 financial results on June 25, 2025, after market close. Founded in 1906, Kewaunee Scientific is a global leader in laboratory, healthcare, and technical furniture products manufacturing. The company's portfolio includes steel and wood casework, fume hoods, modular systems, and biological safety cabinets. Headquartered in Statesville, NC, the company operates manufacturing facilities in both Statesville and Bangalore, India. Through its recently acquired subsidiary Nu Aire, founded in 1971, Kewaunee has expanded its product line to include biological safety cabinets, CO2 incubators, and ultralow freezers, with manufacturing facilities in Minnesota.

Kewaunee Scientific (NASDAQ: KEQU) has announced an amendment to its share repurchase program on March 12, 2025. The Board of Directors has authorized the repurchase of an additional 100,000 shares of common stock, adding to the 11,176 shares still authorized under the existing program that began September 1, 2023.

The company temporarily paused repurchases to focus on the acquisition of Nu Aire, Inc., which closed on November 1, 2024, after repurchasing the maximum allowable shares under their prior credit agreement between October 2023 and April 2024. Share repurchases resumed on February 28, 2025.

The program's timing and amount will be determined by management based on capital needs, stock price, and market conditions. The company maintains flexibility to suspend or discontinue the program at any time.

Kewaunee Scientific (NASDAQ: KEQU) reported its Q3 FY2025 results with sales of $67.17 million, up 43.6% year-over-year. However, pre-tax earnings decreased 63.7% to $1.28 million, with diluted EPS falling to $0.45 from $0.85.

The quarter included costs related to the Nu Aire acquisition, completed on November 1, 2024. Adjusting for acquisition and integration costs of $2.51 million, adjusted pre-tax earnings were $3.79 million, up 7.8% YoY, with adjusted EPS of $1.09.

Key metrics include:

• Order backlog: $221.6 million (up from $152.3 million YoY)
• Domestic sales: $51.98 million (+63.6% YoY)
• International sales: $15.19 million (+1.2% YoY)
• Cash position: $12.34 million
• Debt-to-equity ratio: 1.29-to-1

The company's Domestic segment showed strong performance, while the International segment faced challenges due to customer site delays. Management remains focused on operational excellence and strategic growth initiatives.

Kewaunee Scientific (NASDAQ: KEQU) has announced it will release its third quarter fiscal year 2025 financial results on March 12, 2025 after market close. The results will be available on the company's website.

Founded in 1906, Kewaunee Scientific is a global leader in laboratory, healthcare, and technical furniture products manufacturing. The company operates manufacturing facilities in Statesville, North Carolina, and Bangalore, India. Through its recently acquired subsidiary Nu Aire, founded in 1971, the company has expanded its portfolio to include biological safety cabinets, CO2 incubators, and ultralow freezers. Nu Aire's facilities are located in Plymouth and Long Lake, Minnesota.

Kewaunee Scientific (NASDAQ: KEQU) reported Q2 FY2025 results with sales of $47.76M, down 5.3% YoY. Pre-tax earnings decreased 18.9% to $3.93M, while net earnings increased to $3.01M from $2.73M. The company's order backlog reached a historic high of $184.4M.

Domestic segment sales grew 6.5% to $36.41M, while International segment sales declined 30.1% to $11.36M due to construction delays in India. The company maintained strong liquidity with $29.66M cash on hand and reduced its debt-to-equity ratio to 0.59-to-1.

On November 1, 2024, Kewaunee completed the acquisition of Nu Aire, Inc., a leading manufacturer of biological safety cabinets and airflow products, incurring $2.3M in acquisition-related expenses during the quarter.